Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NexImmune, Inc. logo — NexImmune, Directing T cell function to restore natural immu...

NexImmune, Inc.

NexImmune, Directing T cell function to restore natural immunity

Founded 2011 United States Gaithersburg, United States 32 employees Post-IPO Equity Total: $87.44M Biopharma, Biotechnology +1

General Information

Company Name NexImmune, Inc.
Founded Year 2011
Location United States Gaithersburg, United States
Employees 32
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with NexImmune, Inc.. To contact NexImmune, Inc., visit neximmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NexImmune, Inc. compare?

A PDF of NexImmune, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NexImmune, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NexImmune, Inc.

NexImmune, Inc. is a publicly traded, clinical stage biotechnology company founded in 2011 and is making strides in the development of T cell immunotherapies through its propriety Artificial Immune Modulation (AIM™) technology. The company is focused on addressing unmet medical needs in oncology, specifically targeting relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy with its lead programs. NexImmune's AIM technology allows for the construction of nanoparticles that mimic the function of synthetic dendritic cells, directing a specific T cell-mediated immune response while reducing potential toxicities. This innovative approach offers attributes of cellular precision, potency, and persistence, positioning the company as a disruptive force in the oncology, autoimmune disorders, and infectious disease spaces. In February 2024, NexImmune secured a notable $3.67MPost-IPO Equity investment, signaling investor confidence in the company's technology and pipeline. The investment underscores the potential for therapeutic impact in various therapy targets and reflects the significant adaptability and flexibility of the AIM platform. As the company continues to advance its product candidates through phases of development, it presents an appealing opportunity for venture capital seeking to engage with a forward-thinking player in the biopharma and biotechnology industries. With its innovative platform and promising pipeline, NexImmune's efforts in directing T cell function to restore natural immunity position it as a compelling investment prospect in the evolving landscape of biotechnology and immunotherapy.

Business keywords: immunotherapy, T cell immunotherapies, cancer treatment, clinical stage, proprietary technology, AIM technology, oncology, autoimmune disorders, pharmaceutical company, immuno-therapeutics, artificial immune modulation, nanoparticles, acute myeloid leukemia, multiple myeloma

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $3.67M -
02 Feb 2024
Convertible Note $50.00M 1
Irving Investors
Irving Investors
08 Jan 2021
Venture Round $7.77M -
22 Feb 2019
Series A $23.00M 3
ArrowMark Partners Piedmont Capital Partners
ArrowMark Partners, Piedmont Capital Partners +1
02 Jan 2018
Venture Round $3.00M 3
New Enterprise Associates Amgen Ventures
New Enterprise Associates, Amgen Ventures +1
18 Jul 2014
Venture Round $1.00K -
02 Feb 2012

NexImmune, Inc. Alternatives & Competitors

View All Alternatives
NexImmune, Inc. vs
Arcellx
Arcellx United States

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

Acquired
121 employees
Biopharma, Biotechnology
Compare NexImmune, Inc. vs Arcellx
NexImmune, Inc. vs
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. United States

Pioneering a Multi-Antigen Approach

Grant
20 employees
Biotechnology, Health and Wellness
Compare NexImmune, Inc. vs Marker Therapeutics, Inc.
NexImmune, Inc. vs
Apexigen
Apexigen United States

Creating Transformative Immunotherapies for Patients with Cancer

Post-IPO Equity
11 employees
Biopharma, Biotechnology
View all alternatives

FAQ About NexImmune, Inc.

NexImmune, Directing T cell function to restore natural immunity
NexImmune, Inc. was founded in 2011.
NexImmune, Inc. is headquartered in Gaithersburg, United States.
NexImmune, Inc. operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on immunotherapy, T cell immunotherapies, cancer treatment and clinical stage.
NexImmune, Inc. has approximately 32 employees.
NexImmune, Inc. has completed 6 funding rounds, raising a total of $87.44M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to NexImmune, Inc. include Arcellx, Marker Therapeutics, Inc., Apexigen, Trillium Therapeutics Inc., Simcha Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NexImmune, Inc. and Arcellx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NexImmune, Inc., https://bouncewatch.com/company/neximmune-inc, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout